Open AccessAssessing Synaptic Density in Alzheimer Disease With Synaptic Vesicle Glycoprotein 2A Positron Emission Tomographic Imaging
Author(s) -
Ming-Kai Chen,
Adam P. Mecca,
Mika Naganawa,
Sjoerd J. Finnema,
Takuya Toyonaga,
Shu-fei Lin,
Soheila Najafzadeh,
Jim Ropchan,
Yihuan Lu,
Julia W. McDonald,
Hannah R. Michalak,
Nabeel Nabulsi,
Amy F.T. Arnsten,
Yiyun Huang,
Richard E. Carson,
Christopher H. van Dyck
Publication year - 2018
Publication title -
jama neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.298
H-Index - 231
eISSN - 2168-6157
pISSN - 2168-6149
DOI - 10.1001/jamaneurol.2018.1836
Subject(s) - pittsburgh compound b , hippocampus , positron emission tomography , hippocampal formation , neuroscience , synaptic vesicle , perforant path , alzheimer's disease , magnetic resonance imaging , chemistry , psychology , medicine , pathology , cognitive impairment , vesicle , cognition , biochemistry , disease , dentate gyrus , radiology , membrane
Synaptic loss is well established as the major structural correlate of cognitive impairment in Alzheimer disease (AD). The ability to measure synaptic density in vivo could accelerate the development of disease-modifying treatments for AD. Synaptic vesicle glycoprotein 2A is an essential vesicle membrane protein expressed in virtually all synapses and could serve as a suitable target for synaptic density.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom